Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx
Conditions
Interventions
Intervention1: TAB.PILOCARPINE: Pilocarpine 5 mg Thrice daily will be given during course of Radiotherapy and 3 months follow up period
Control Intervention1: No placebo: No intervention in control gr
Sponsors
SVIMS
Eligibility
Inclusion criteria
Inclusion criteria: Histo pathologically proven squamous cell carcinoma of head & neck [oral cavity, oropharynx, nasopharynx, hypopharynx, larynx] Age : 18 -70 years Patients with ECOG performance status of 0-2 Stage I to IVb [AJCC : 8th edition] Patients receiving definitive or adjuvant RT (postoperative cases) with or without concurrent chemotherapy Patients who have given approved informed consent
Exclusion criteria
Exclusion criteria: Patients previously treated with radiotherapy to head & neck region Patients receiving palliative radiotherapy Cancers of salivary glands Patients with surgical removal of parotid / submandibular glands Patients with ECOG performance status of 3-4 [Appendix II] Patients allergic to pilocarpine Patients receiving tricyclic antidepressants, beta blockers & anti histaminics Patients suffering with closed angle glaucoma, asthma, COPD & coronary artery disease Pregnant & lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stimulated and unstimulated Salivary flowTimepoint: 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual Analog ScoreTimepoint: 3 months | — |
Countries
India
Contacts
Public ContactCherwin Venati
Sri Venkateswara Institute of Medical Sciences
Outcome results
None listed